U.S. markets close in 5 hours 49 minutes
  • S&P 500

    4,121.82
    -18.24 (-0.44%)
     
  • Dow 30

    32,802.05
    -30.49 (-0.09%)
     
  • Nasdaq

    12,473.17
    -171.29 (-1.35%)
     
  • Russell 2000

    1,923.23
    -17.98 (-0.93%)
     
  • Crude Oil

    91.96
    +1.20 (+1.32%)
     
  • Gold

    1,813.20
    +8.00 (+0.44%)
     
  • Silver

    20.53
    -0.08 (-0.41%)
     
  • EUR/USD

    1.0242
    +0.0047 (+0.46%)
     
  • 10-Yr Bond

    2.8030
    +0.0380 (+1.37%)
     
  • GBP/USD

    1.2112
    +0.0030 (+0.25%)
     
  • USD/JPY

    134.9850
    +0.0120 (+0.01%)
     
  • BTC-USD

    23,035.17
    -1,094.03 (-4.53%)
     
  • CMC Crypto 200

    535.24
    -22.11 (-3.97%)
     
  • FTSE 100

    7,494.85
    +12.48 (+0.17%)
     
  • Nikkei 225

    27,999.96
    -249.28 (-0.88%)
     

GBT Announces New Employment Inducement Grants

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., July 07, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2022, the compensation committee of GBT’s board of directors granted 22 new employees options to purchase an aggregate of 10,600 shares of the company’s common stock with a per share exercise price of $32.80 and restricted stock units for an aggregate 76,600 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan). 

The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by GBT’s board of directors in January 2017 and has been amended and restated from time to time.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). Founded in 2011, GBT is delivering on its goal to transform the treatment and care of SCD, a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor), the first FDA-approved medicine that directly inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation HbS polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com